The Company is now positioning itself to further a
Post# of 72440
(Total Views: 569)
Posted On: 04/19/2019 8:03:00 PM
The Company is now positioning itself to further advance Brilacidin, most immediately, in its planned Phase 3 Oral Mucositis program, and in mid-stage testing for Inflammatory Bowel Disease.
Then this same PR- In other news, the Company will commence Scientific Advice discussions with the European Medicines Agency (EMA) this week, via a scheduled meeting, to review plans for the international Phase 3 Brilacidin Oral Mucositis program.
"most immediately" makes it sounds like US P3 preparations ready to start now independent of EU plans. Hopefully big news next week. Really exciting.
Then this same PR- In other news, the Company will commence Scientific Advice discussions with the European Medicines Agency (EMA) this week, via a scheduled meeting, to review plans for the international Phase 3 Brilacidin Oral Mucositis program.
"most immediately" makes it sounds like US P3 preparations ready to start now independent of EU plans. Hopefully big news next week. Really exciting.
(6)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼